Synonyms: Olinvyk® | TRV130 | TRV130A
oliceridine is an approved drug (FDA (2020))
Compound class:
Synthetic organic
Comment: Oliceridine (TRV130) is an opioid compound. It was developed to exhibit biased-signalling (specifically bias towards G protein signalling), with the aim of reducing the adverse effects associated with use of other opioid drugs [1-2].
|
|
No information available. |
Summary of Clinical Use ![]() |
Oliceridine (TRV130) is administered intravenously. It was evaluated in human clinical trial for the treatment of acute severe pain [3]. Click here to view the full list of oliceridine trials registered at ClinicalTrials.gov. Oliceridine received FDA approval in August 2020, for the management of acute pain that requires intravenous opioid analgesia and that is not adequately responsive to alternative treatments. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
Oliceridine is an agonist of the opioid μ receptor (OPRM1) [1]. |
Pharmacokinetics ![]() |
Absorption/Distribution |
Initial pharmacokinetic and pharmacodynamic data from clinical use of this compound is reported by Soergel et al (2014) [3]. |